{Reference Type}: Journal Article
{Title}: The new European Medicines Agency guideline on antidepressants: a guide for researchers and drug developers.
{Author}: Butlen-Ducuing F;Haberkamp M;Aislaitner G;Bałkowiec-Iskra E;Mattila T;Doucet M;Kollb-Sielecka M;Balabanov P;Leuchs AK;Elferink A;
{Journal}: Eur Psychiatry
{Volume}: 67
{Issue}: 1
{Year}: 2023 Dec 15
{Factor}: 7.156
{DOI}: 10.1192/j.eurpsy.2023.2479
{Abstract}: According to the World Health Organization (WHO), depressive disorders are currently considered as one of the most disabling medical conditions in the world with one of the highest disability-adjusted life years [1] and this situation has apparently been further worsened during the COVID-19 pandemic [2]. Up to two thirds of patients with major depressive disorders (MDD) do not achieve full remission following an adequate first line standard of care and/or experience residual symptoms such as anxiety, impaired cognition, fatigue, sleep disturbance, or anhedonia [3]. Several attempts are often needed to find the most suitable treatment [4]. Thus, there is a need for medicinal products with better efficacy (e.g., faster onset of action, higher rates of response and remission), improved safety and/or more personalised profiles [5].